Sodium Chloride 0

DRUG3 trials

Sponsors

Seelos Therapeutics Inc., Universite De Liege, CHU De Liege, Elliniko Institouto Meletis Tis Sipsis

Conditions

Disorder of ConsciousnessInfection and sepsisSpinocerebellar Ataxia type-3 (SCA3)severe brain injury

Phase 2

A DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED TRIAL TO ASSESS SAFETY AND EFFICACY OF SLS-005 (TREHALOSE INJECTION, 90.5 MG/ML FOR INTRAVENOUS INFUSION) FOR THE TREATMENT OF ADULTS WITH SPINOCEREBELLAR ATAXIA

CompletedCTIS2022-501004-10-00

Seelos Therapeutics Inc.Spinocerebellar Ataxia type-3 (SCA3)

Start: 2023-01-30End: 2024-02-12Target: 58Updated: 2023-03-10

Treating severe brain-injured patients with apomorphine : a behavioural and neuroimaging study

RecruitingCTIS2023-504631-40-01

Universite De Liege, CHU De LiegeDisorder of Consciousness, severe brain injury

Start: 2018-09-05Target: 102Updated: 2025-07-24

Phase 3

THE ROLE OF PANCREATIC STONE PROTEIN (PSP) AND PSP-GUIDED EARLY MEROPENEM TREATMENT TO MITIGATE SEPSIS RISK AT THE EMERGENCY DEPARTMENT: THE PROMISE DOUBLE BLIND, PHASE III, RANDOMIZED CONTROLLED CLINICAL TRIAL

Not yet recruitingCTIS2025-525006-37-00

Elliniko Institouto Meletis Tis SipsisInfection and sepsis

Target: 398Updated: 2026-04-29